Gemini Therapeutics, Inc. (GMTX)
| Market Cap | 688.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 42.92M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 26 |
| Last Price | $15.20 |
| Previous Close | $15.00 |
| Change ($) | 0.20 |
| Change (%) | 1.33% |
| Day's Open | 14.78 |
| Day's Range | 13.86 - 15.25 |
| Day's Volume | 304,610 |
| 52-Week Range | 9.80 - 15.50 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related ma...
SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.
Gemini Therapeutics Inc (NASDAQ: GMTX) concludes enrollment in its Phase 2a ReGAtta study evaluating GEM103, a recombinant human complement factor H (CFH), in dry Age-related macular degenerat...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related ma...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related ma...
About GMTX
Gemini Therapeutics, a precision medicine company, focuses on the development of new therapies for patients suffering from dry AMD and linked diseases. The company was founded in 2015 and is based in Cambridge, Massachusetts.
| Industry Biotechnology | Founded 2015 |
| CEO Jason Patrick Meyenburg M.B.A., M.D. | |
| Stock Exchange NASDAQ | Ticker Symbol GMTX |